This article will review the latest evidence-based management of breast, ovarian, prostate and pancreatic cancer associated with BRCA1/2 PVs/LPVs as well as discuss some of the challenges in oncology therapeutics. This evidence concerns the gene BRCA1 and pancreatic neoplasm.